A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for Twelve Weeks, Compared to Placebo, in Asthmatics Symptomatic on Low Dose ICS
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs AZD 7594 (Primary) ; Budesonide; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms GRANIT
- Sponsors AstraZeneca
- 18 Nov 2019 Status changed from active, no longer recruiting to completed.
- 17 Nov 2019 This trial is completed in Germany (Global End Date: 2019-09-30), according to European Clinical Trials Database record.
- 13 Nov 2019 This trial is completed in Bularia and Hungary (Global End Date: 30 Sep 2019), according to European Clinical Trials Database record.